Life Biosciences announced the close of a fully subscribed $80 million Series D financing to support the advancement of its cellular rejuvenation therapies targeting diseases of aging.
The proceeds will fund operations into the second half of 2027, including the completion of the company’s Phase 1 clinical trial of its lead candidate, ER-100, as well as continued development of its Partial Epigenetic Reprogramming platform across multiple therapeutic areas.
Life Biosciences is focused on reversing and preventing age-related diseases by targeting the underlying biological drivers of aging. Its Partial Epigenetic Reprogramming platform is designed to restore aged and damaged cells to a more youthful state through the expression of three transcription factors, OCT4, SOX2, and KLF4. This approach aims to address a root cause of aging at the epigenetic level, with potential applications across a wide range of chronic conditions.
The company’s lead program, ER-100, is currently being evaluated in a Phase 1 clinical trial for optic neuropathies, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The study is assessing safety, tolerability, and early signals of efficacy, including improvements in visual function.
Optic neuropathies are characterized by damage to retinal ganglion cells, which do not naturally regenerate, leading to permanent vision impairment. Existing treatments do not address the underlying neuronal degeneration, highlighting a significant unmet need for therapies capable of protecting or restoring these cells.
Beyond ER-100, Life Biosciences is expanding its pipeline to explore additional indications, leveraging the versatility of its platform to target multiple diseases associated with aging.
KEY QUOTE:
“We are encouraged by the strong participation in this financing, which reflects the growing interest in our platform and the opportunity we have to reverse multiple diseases of aging. This support enables us to advance our lead program, ER-100, through key clinical milestones while continuing the expansion of our pipeline, positioning Life Bio to deliver disease-modifying solutions for patients.”
Jerry McLaughlin, Chief Executive Officer, Life Biosciences
